# Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease

> **NCT02203578** · NA · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 1 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** romidepsin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02203578
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2016-06-14
- **Final completion:** 2016-06-14
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203578, "Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02203578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*